Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
2. 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1h-benzimidazole
3. Aciphex
4. Dexrabeprazole
5. E 3810
6. E3810
7. Ly 307640
8. Ly-307640
9. Ly307640
10. Pariet
11. Rabeprazole
12. Sodium, Rabeprazole
1. 117976-90-6
2. Rebeprazole Sodium
3. Pariet
4. Aciphex
5. Rabeprazole Sodium Salt
6. Dexrabeprazole Sodium
7. Rabeprazole (sodium)
8. (s)-rabeprazole Sodium Salt
9. Aciphex Sprinkle
10. Ly307640 Sodium
11. Sodium Rabeprazole
12. Rabeprazole Sodium [usan]
13. Idiazole
14. Rabeprazole Na
15. Chebi:8769
16. 171440-19-0
17. Ly-307640
18. E3810
19. E-3810 Sodium
20. Sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
21. Ly-307640 Sodium
22. 3l36p16u4r
23. 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
24. 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridyl)methyl)sulfinyl)benzimidazole Sodium Salt
25. Nsc-759270
26. Dsstox_cid_24205
27. Dsstox_rid_80118
28. Dsstox_gsid_44205
29. 1h-benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, Sodium Salt (1:1)
30. Rabicip
31. Pepcia
32. Aciphex Sodium
33. Ly 307640 Sodium
34. Habeprazole Sodium
35. Sodium 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide
36. Sodium 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-ide
37. Smr000550493
38. Cas-117976-90-6
39. Ncgc00159518-02
40. E 3810
41. Pariete
42. Unii-3l36p16u4r
43. Pariprazole Sodium
44. Dexrabeprazolesodium
45. Rebeprazole Sodium;
46. Aciphex (tn)
47. Pariet (tn)
48. Rebeprazole Sodium Salt
49. Rabeprazole Sodium- Bio-x
50. Mls001165734
51. Mls006010621
52. Schembl140494
53. Rabeprazole Na [vandf]
54. Chembl1200930
55. Dtxsid3044205
56. Rabeprazole Sodium [jan]
57. Hy-b0656a
58. Rabeprazole Sodium (jp17/usp)
59. Ex-a176
60. Hms2093h10
61. Hms2231e04
62. Hms3373b05
63. Rabeprazole Sodium [mart.]
64. Bcp06639
65. Rabeprazole Sodium [usp-rs]
66. Rabeprazole Sodium [who-dd]
67. Tox21_111736
68. Tox21_302317
69. Ac-715
70. Bdbm50247881
71. Mfcd02092688
72. Rabeprazole Sodium Salt [mi]
73. S4665
74. Rabeprazole Sodium, >=98% (hplc)
75. Akos015895734
76. Akos015962116
77. Akos025310160
78. Tox21_111736_1
79. Am81231
80. Ccg-213574
81. Ccg-268423
82. Nsc 759270
83. Rabeprazole Sodium [orange Book]
84. Ncgc00159518-05
85. Ncgc00255838-01
86. Rabeprazole Sodium [ep Monograph]
87. As-13338
88. Br167318
89. Rabeprazole Sodium [usp Monograph]
90. Ft-0631090
91. Ft-0689461
92. R0115
93. C07865
94. D00724
95. F17418
96. 976r906
97. Sr-01000799133
98. J-010726
99. Q-201655
100. Sr-01000799133-2
101. Q27108142
102. [2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]benzimidazol-1-yl]sodium
103. Sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole
104. 1h-benzimidazole,2-[[[4-(3-methoxypropoxy)- 3-methyl-2-pyridinyl]methyl]sulfinyl]-,sodium Salt
105. 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole, Sodium Salt
106. Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
| Molecular Weight | 381.4 g/mol |
|---|---|
| Molecular Formula | C18H20N3NaO3S |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 8 |
| Exact Mass | 381.11230696 g/mol |
| Monoisotopic Mass | 381.11230696 g/mol |
| Topological Polar Surface Area | 81.5 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 446 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Aciphex |
| PubMed Health | Rabeprazole (By mouth) |
| Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
| Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
| Active Ingredient | Rabeprazole sodium |
| Dosage Form | Tablet, delayed release |
| Route | oral; Oral |
| Strength | 20mg |
| Market Status | Prescription |
| Company | Eisai; Eisai Medcl Res |
| 2 of 4 | |
|---|---|
| Drug Name | Rabeprazole sodium |
| Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
| Active Ingredient | Rabeprazole sodium |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | 20mg |
| Market Status | Prescription |
| Company | Mylan Pharms; Kremers Urban Dev; Teva Pharms Usa; Torrent Pharms; Lupin; Dr Reddys Labs |
| 3 of 4 | |
|---|---|
| Drug Name | Aciphex |
| PubMed Health | Rabeprazole (By mouth) |
| Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
| Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
| Active Ingredient | Rabeprazole sodium |
| Dosage Form | Tablet, delayed release |
| Route | oral; Oral |
| Strength | 20mg |
| Market Status | Prescription |
| Company | Eisai; Eisai Medcl Res |
| 4 of 4 | |
|---|---|
| Drug Name | Rabeprazole sodium |
| Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
| Active Ingredient | Rabeprazole sodium |
| Dosage Form | Tablet, delayed release |
| Route | Oral |
| Strength | 20mg |
| Market Status | Prescription |
| Company | Mylan Pharms; Kremers Urban Dev; Teva Pharms Usa; Torrent Pharms; Lupin; Dr Reddys Labs |
Treatment of duodenal ulcer, Treatment of gastric ulcer, Treatment of gastro-oesophageal reflux disease, Treatment of Helicobacter pylori in patients with peptic ulcer disease, Treatment of Zollinger-Ellison syndrome
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-053
Start Marketing Date : 2023-01-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-013
Start Marketing Date : 2020-11-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 55111-055
Start Marketing Date : 2010-01-30
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Neuland Laboratories- A dedicated 100% API provider.
NDC Package Code : 58032-1023
Start Marketing Date : 2018-10-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65862-414
Start Marketing Date : 2024-01-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65977-0033
Start Marketing Date : 1999-08-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65372-1132
Start Marketing Date : 2009-03-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 53069-0980
Start Marketing Date : 2017-12-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 53069-0650
Start Marketing Date : 2005-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 52286-0017
Start Marketing Date : 2009-11-04
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
2-chloroxymethyl-4,-(3Methoxy Propoxy)-3-Methyl Py...
CAS Number : 153259-31-5
End Use API : Rabeprazole Sodium
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
2-[[[4-(3-Methoxy Propoxy-3-methyl-2Pyridyl] Methy...
CAS Number : 117977-21-6
End Use API : Rabeprazole Sodium
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
2-Hydroxymethyl-4,-(3-methoxy propoxy)-3-methyl py...
CAS Number : 675198-19-3
End Use API : Rabeprazole Sodium
About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...
2-Chloromethyl-4,-(3-methoxy propoxy)-3-methyl pyr...
CAS Number : 153259-31-5
End Use API : Rabeprazole Sodium
About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...
2-(((4-(3-methoxy propoxy-3-methyl-2- pyridyl)meth...
CAS Number : 117977-21-6
End Use API : Rabeprazole Sodium
About The Company : Chemeca Drugs Private Limited was erstwhile M/s. Vegesna Laboratories Pvt Limited. M/s. Vegesna Laboratories Pvt Limited is a Private limited company having its...
CAS Number : 583-39-1
End Use API : Rabeprazole Sodium
About The Company : Chemox ChemoPharma Industries was started in 2006 by the eminent entrepreneur Mr. K.H.Vekariya. Today M/s Chemox ChemoPharma Industries is one of the leading m...
2[[[4(3Methoxypropoxy) 3methylpyridinyl] methyl] t...
CAS Number : 117977-21-6
End Use API : Rabeprazole Sodium
About The Company : Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other activ...
2{[ 4(3Methoxypropoxy) 3methylpyridine2yl] methylt...
CAS Number : 117977-21-6
End Use API : Rabeprazole Sodium
About The Company : Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other activ...
Pyridine 2(chloromethyl) 4 (3methoxypropoxy) 3meth...
CAS Number : 153259-31-5
End Use API : Rabeprazole Sodium
About The Company : Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other activ...
Pyridine 4 chloro 2,3 dimethyl 1 oxide
CAS Number : 59886-90-7
End Use API : Rabeprazole Sodium
About The Company : Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other activ...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - CAPSULE, DELAYED RELEASE;ORAL - 10MG
USFDA APPLICATION NUMBER - 204736
DOSAGE - CAPSULE, DELAYED RELEASE;ORAL - 5MG
USFDA APPLICATION NUMBER - 204736
DOSAGE - TABLET, DELAYED RELEASE;ORAL - 10MG ...DOSAGE - TABLET, DELAYED RELEASE;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 20973
DOSAGE - TABLET, DELAYED RELEASE;ORAL - 20MG
USFDA APPLICATION NUMBER - 20973
Related Excipient Companies
Minakem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Evonik
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Faran Shimi Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Minbiotech
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Alcedo Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Avesta Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Controlled & Modified Release
Disintegrants & Superdisintegrants
Solubilizers
Granulation
Direct Compression
Thickeners and Stabilizers
Lubricants & Glidants
Taste Masking
Parenteral
Film Formers & Plasticizers
Topical
Chewable & Orodispersible Aids
Co-Processed Excipients
Emulsifying Agents
Rheology Modifiers
API Stability Enhancers
Empty Capsules
Surfactant & Foaming Agents
Coloring Agents
Vegetarian Capsules
Soft Gelatin
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
BioAnalytical Methods
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Analytical Methods
ABOUT THIS PAGE
60
PharmaCompass offers a list of Rabeprazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rabeprazole manufacturer or Rabeprazole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rabeprazole manufacturer or Rabeprazole supplier.
PharmaCompass also assists you with knowing the Rabeprazole API Price utilized in the formulation of products. Rabeprazole API Price is not always fixed or binding as the Rabeprazole Price is obtained through a variety of data sources. The Rabeprazole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dexrabeprazole Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dexrabeprazole Sodium, including repackagers and relabelers. The FDA regulates Dexrabeprazole Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dexrabeprazole Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dexrabeprazole Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dexrabeprazole Sodium supplier is an individual or a company that provides Dexrabeprazole Sodium active pharmaceutical ingredient (API) or Dexrabeprazole Sodium finished formulations upon request. The Dexrabeprazole Sodium suppliers may include Dexrabeprazole Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Dexrabeprazole Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dexrabeprazole Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Dexrabeprazole Sodium active pharmaceutical ingredient (API) in detail. Different forms of Dexrabeprazole Sodium DMFs exist exist since differing nations have different regulations, such as Dexrabeprazole Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dexrabeprazole Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Dexrabeprazole Sodium USDMF includes data on Dexrabeprazole Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dexrabeprazole Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dexrabeprazole Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Dexrabeprazole Sodium Drug Master File in Japan (Dexrabeprazole Sodium JDMF) empowers Dexrabeprazole Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Dexrabeprazole Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Dexrabeprazole Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Dexrabeprazole Sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Dexrabeprazole Sodium Drug Master File in Korea (Dexrabeprazole Sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dexrabeprazole Sodium. The MFDS reviews the Dexrabeprazole Sodium KDMF as part of the drug registration process and uses the information provided in the Dexrabeprazole Sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Dexrabeprazole Sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dexrabeprazole Sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Dexrabeprazole Sodium suppliers with KDMF on PharmaCompass.
A Dexrabeprazole Sodium CEP of the European Pharmacopoeia monograph is often referred to as a Dexrabeprazole Sodium Certificate of Suitability (COS). The purpose of a Dexrabeprazole Sodium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dexrabeprazole Sodium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dexrabeprazole Sodium to their clients by showing that a Dexrabeprazole Sodium CEP has been issued for it. The manufacturer submits a Dexrabeprazole Sodium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dexrabeprazole Sodium CEP holder for the record. Additionally, the data presented in the Dexrabeprazole Sodium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dexrabeprazole Sodium DMF.
A Dexrabeprazole Sodium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dexrabeprazole Sodium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dexrabeprazole Sodium suppliers with CEP (COS) on PharmaCompass.
A Dexrabeprazole Sodium written confirmation (Dexrabeprazole Sodium WC) is an official document issued by a regulatory agency to a Dexrabeprazole Sodium manufacturer, verifying that the manufacturing facility of a Dexrabeprazole Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dexrabeprazole Sodium APIs or Dexrabeprazole Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Dexrabeprazole Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Dexrabeprazole Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dexrabeprazole Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dexrabeprazole Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dexrabeprazole Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dexrabeprazole Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dexrabeprazole Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dexrabeprazole Sodium suppliers with NDC on PharmaCompass.
Dexrabeprazole Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dexrabeprazole Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dexrabeprazole Sodium GMP manufacturer or Dexrabeprazole Sodium GMP API supplier for your needs.
A Dexrabeprazole Sodium CoA (Certificate of Analysis) is a formal document that attests to Dexrabeprazole Sodium's compliance with Dexrabeprazole Sodium specifications and serves as a tool for batch-level quality control.
Dexrabeprazole Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Dexrabeprazole Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dexrabeprazole Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Dexrabeprazole Sodium EP), Dexrabeprazole Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dexrabeprazole Sodium USP).
